Bryggargatan 10
Stockholm 111 21
Sweden
46 7 62 19 37 38
https://www.ibtherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Staffan Stromberg Ph.D. | Chief Executive Officer | 5.33M | N/A | 1967 |
Ms. Maria Ekdahl | Chief Financial Officer | N/A | N/A | 1973 |
Mr. Anders Kronström M.B.A., M.S. | Chief Operating Officer | 500k | N/A | 1967 |
Dr. Thomas J. Schnitzer M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Sanjiv Sharma M.B.A. | Head of Medical Affairs | N/A | N/A | 1957 |
Prof. Jonas Rastad M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1950 |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Infant Bacterial Therapeutics AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.